Exforge 5/80, 5/160, 10/160 film-coated tablets
*Company:
Novartis Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 04 March 2024
File name
Exforge_REG PIL_PF24-0027_25.01.2024_clean_IPHA.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 08 February 2024
File name
Exforge_REG SPC_PF24-0027-Jan_2024_clean_IPHA.pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 15 November 2022
File name
Exforge_REG PIL_PF22-0220_Nov2022_clean_IPHA.pdf
Reasons for updating
- Change to section 3 - overdose, missed or forgotten doses
Updated on 15 November 2022
File name
Exforge_REG SPC_PF22-0220_Nov2022_clean_IPHA.pdf
Reasons for updating
- Change to section 4.9 - Overdose
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 15 October 2021
File name
Exforge_REG PIL_PF21-0266_IPHA.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to other sources of information section
Updated on 05 May 2021
File name
Exforge_REG PIL_PF21-0073_IPHA.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 22 November 2019
File name
Exforge FCT_REG PIL_PF 19-0168_IPHA.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 25 April 2019
File name
Exforge FCT 1136812_B18_IE_p1_LFT_X-4_IPHA.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 28 March 2019
File name
REG_SmPC_Exforge Family_PF 18-0138 MAH Transfer_IPHA.pdf
Reasons for updating
- File format updated to PDF
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 10 July 2018
File name
Exforge family_REG_PIL_1136812_A18_IE_p1_LFT_X-4_.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 04 July 2018
File name
REG_SmPC_Exforge Family_PF 18-0138 MAH Transfer_clean.docx
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 27 June 2018
File name
Exforge REG SmPC PF 18-0163_CLEAN.docx
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 16 May 2017
File name
PIL_17161_244.pdf
Reasons for updating
- New PIL for new product
Updated on 04 April 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)